• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Impact of Laboratory Practice Changes on the Diagnosis of Tuberculosis with the Introduction of Xpert MTB/RIF in Kiribati.实验室操作变化对基里巴斯引入Xpert MTB/RIF后结核病诊断的影响
Hawaii J Med Public Health. 2018 Feb;77(2):30-34.
2
Evaluation of the Xpert® MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia.在纳米比亚评估Xpert® MTB/RIF检测法和显微镜检查法用于诊断结核分枝杆菌的情况。
Infect Dis Poverty. 2017 Jan 11;6(1):13. doi: 10.1186/s40249-016-0213-y.
3
Xpert MTB/RIF assay can be used on archived gastric aspirate and induced sputum samples for sensitive diagnosis of paediatric tuberculosis.Xpert MTB/RIF检测可用于存档的胃抽吸物和诱导痰样本,以对儿童结核病进行敏感诊断。
BMC Microbiol. 2015 Sep 29;15:191. doi: 10.1186/s12866-015-0528-z.
4
Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial.南非开普敦重症监护病房的结核病负担,以及对 Xpert MTB/RIF 检测在诊断肺结核方面的准确性及其对患者结局影响的评估:一项采用嵌套随机对照试验的疾病负担前瞻性研究。
Lancet Respir Med. 2015 Aug;3(8):621-30. doi: 10.1016/S2213-2600(15)00198-8. Epub 2015 Jul 22.
5
Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study.在初级保健环境中使用 Xpert MTB/RIF 检测呼吸道标本快速诊断非洲儿童肺结核:一项前瞻性研究。
Lancet Glob Health. 2013 Aug;1(2):e97-e104. doi: 10.1016/S2214-109X(13)70036-6. Epub 2013 Jul 24.
6
Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.评估 Xpert MTB/RIF assay 在高 HIV 流行环境下用于诊断肺结核的效果。
Am J Respir Crit Care Med. 2011 Jul 1;184(1):132-40. doi: 10.1164/rccm.201101-0056OC. Epub 2011 Apr 14.
7
Added value of molecular assay Xpert MTB/RIF compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country.分子检测 Xpert MTB/RIF 比痰涂片显微镜检查在低流行国家评估结核病传播风险的附加价值。
Clin Microbiol Infect. 2016 Jul;22(7):613-9. doi: 10.1016/j.cmi.2016.04.010. Epub 2016 Apr 29.
8
Evaluation of Xpert MTB/RIF assay in children with presumed pulmonary tuberculosis in Papua New Guinea.在巴布亚新几内亚疑似肺结核儿童中对Xpert MTB/RIF检测法的评估。
Paediatr Int Child Health. 2018 May;38(2):97-105. doi: 10.1080/20469047.2017.1319898. Epub 2017 May 11.
9
Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study.在撒哈拉以南非洲地区,采用 Xpert MTB/RIF 检测法对胃抽吸物进行检测诊断儿童结核病的评估:一项前瞻性描述性研究。
Lancet Infect Dis. 2013 Jan;13(1):36-42. doi: 10.1016/S1473-3099(12)70245-1. Epub 2012 Nov 5.
10
Reassessment of the positive predictive value and specificity of Xpert MTB/RIF: a diagnostic accuracy study in the context of community-wide screening for tuberculosis.Xpert MTB/RIF 阳性预测值和特异性的再评估:在社区范围内进行结核病筛查背景下的诊断准确性研究。
Lancet Infect Dis. 2016 Sep;16(9):1045-1051. doi: 10.1016/S1473-3099(16)30067-6. Epub 2016 Jun 8.

引用本文的文献

1
Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012-2019: Are We on the Right Track?乌兹别克斯坦 2012-2019 年耐药结核病分子诊断检测扩大化:我们是否走在正确的轨道上?
Int J Environ Res Public Health. 2021 Apr 28;18(9):4685. doi: 10.3390/ijerph18094685.
2
Challenges and Progress with Diagnosing Pulmonary Tuberculosis in Low- and Middle-Income Countries.低收入和中等收入国家肺结核诊断面临的挑战与进展
Diagnostics (Basel). 2018 Nov 23;8(4):78. doi: 10.3390/diagnostics8040078.
3
Has the utilisation of Xpert MTB/RIF in Manicaland Province, Zimbabwe, improved with new guidance on whom to test?在津巴布韦马尼卡兰省,关于检测对象的新指南是否提高了Xpert MTB/RIF检测法的使用率?
Public Health Action. 2018 Sep 21;8(3):124-129. doi: 10.5588/pha.18.0028.
4
What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?低收入和中等收入国家的国家结核病控制规划要如何做才能在2030年前终结结核病?
F1000Res. 2018 Jul 5;7. doi: 10.12688/f1000research.14821.1. eCollection 2018.

本文引用的文献

1
Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert(®) MTB/RIF in Zimbabwe.在津巴布韦使用Xpert(®)MTB/RIF检测出的耐利福平结核病患者的诊断与治疗
Public Health Action. 2016 Jun 21;6(2):122-8. doi: 10.5588/pha.16.0005.
2
Tuberculosis case burden and treatment outcomes in children, adults and older adults, Vanuatu, 2007-2011.2007 - 2011年瓦努阿图儿童、成年人及老年人的结核病负担与治疗结果
Public Health Action. 2014 Jun 21;4(Suppl 1):S14-8. doi: 10.5588/pha.13.0074.
3
The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.使用常规收集的健康数据进行研究的报告(RECORD)声明
PLoS Med. 2015 Oct 6;12(10):e1001885. doi: 10.1371/journal.pmed.1001885. eCollection 2015 Oct.
4
Evaluation of the implementation of the Xpert® MTB/RIF assay in Fiji.斐济Xpert® MTB/RIF检测法实施情况评估。
Public Health Action. 2014 Sep 21;4(3):179-83. doi: 10.5588/pha.14.0025.
5
Countrywide roll-out of Xpert(®) MTB/RIF in Swaziland: the first three years of implementation.斯威士兰全国推广Xpert(®) MTB/RIF:实施的头三年
Public Health Action. 2015 Jun 21;5(2):140-6. doi: 10.5588/pha.15.0001.
6
Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.Xpert MTB/RIF 检测在九个国家的早期规划实施结果。
BMC Infect Dis. 2014 Jan 2;14:2. doi: 10.1186/1471-2334-14-2.
7
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.结核病诊断学的进展:Xpert MTB/RIF 检测法和即时检测点的未来前景。
Lancet Infect Dis. 2013 Apr;13(4):349-61. doi: 10.1016/S1473-3099(13)70008-2. Epub 2013 Mar 24.
8
Diagnosis of pulmonary tuberculosis.肺结核诊断。
Curr Opin Pulm Med. 2013 May;19(3):280-8. doi: 10.1097/MCP.0b013e32835f1b70.
9
HIV and tuberculosis--science and implementation to turn the tide and reduce deaths.艾滋病毒和结核病——科学与实施以扭转局面和减少死亡。
J Int AIDS Soc. 2012;15(2):17396. doi: 17396.
10
Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?Xpert® MTB/RIF 用于低收入国家的国家结核病规划:何时、何地以及如何使用?
Int J Tuberc Lung Dis. 2011 Dec;15(12):1567-72. doi: 10.5588/ijtld.11.0392. Epub 2011 Oct 13.

实验室操作变化对基里巴斯引入Xpert MTB/RIF后结核病诊断的影响

Impact of Laboratory Practice Changes on the Diagnosis of Tuberculosis with the Introduction of Xpert MTB/RIF in Kiribati.

作者信息

Tonganibeia Alfred, Harries Anthony D, Merilles Onofre Edwin A, Tarataake Tekaibeti, Tiira Teatao, Kienene Takeieta

机构信息

Ministry of Health and Medical Services, Kiribati (AT, TTarataake, TTiira, TK).

International Union Against Tuberculosis and Lung Disease, Paris, France and London School of Hygiene and Tropical Medicine, London, UK (ADH).

出版信息

Hawaii J Med Public Health. 2018 Feb;77(2):30-34.

PMID:29435388
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5801526/
Abstract

The Republic of Kiribati, Central Pacific, has the largest tuberculosis epidemic in the region. There is a national tuberculosis control program, which has used smear microscopy for acid-fast bacilli as the main diagnostic tool for many years. In 2015, an Xpert MTB/RIF machine was procured and became functional within the tuberculosis hospital. The aim of this cross-sectional study, using routinely collected data, was to determine the effects of introducing Xpert MTB/RIF on laboratory smear microscopy practices and the pattern of registered tuberculosis cases. Between February 2015 and January 2016, there were 220 Xpert MTB/RIF assays performed with 6.4% errors and 15% detection of one patient showed rifampicin-resistance. One year before and after introducing Xpert MTB/RIF, the number of presumptive tuberculosis patients increased by 9% from 2,138 to 2,322. There were no changes in demographic characteristics, smear-positive results, or acid-fast bacilli grade between the two periods. The number of specimens cultured for significantly declined from 638 to zero, with 76 positive MTB cultures before and none after introducing Xpert MTB/RIF. There was a significant change in the profile of registered tuberculosis cases with more children (34% versus 21%) and fewer bacteriologically-confirmed cases (29% versus 43%) - .001. Since the deployment of Xpert MTB/RIF in Kiribati, there have been a small number of assays performed and this has been associated with no adverse effects on smear microscopy, a stoppage in mycobacterial cultures, and a change in the types and categories of diagnosed tuberculosis.

摘要

位于中太平洋的基里巴斯共和国是该地区结核病疫情最为严重的国家。该国设有国家结核病控制项目,多年来一直将痰涂片显微镜检查抗酸杆菌作为主要诊断工具。2015年,采购了一台Xpert MTB/RIF检测仪,并在结核病医院投入使用。本横断面研究利用常规收集的数据,旨在确定引入Xpert MTB/RIF对实验室痰涂片显微镜检查操作以及登记结核病病例模式的影响。2015年2月至2016年1月期间,共进行了220次Xpert MTB/RIF检测,误差率为6.4%,15%的检测发现一名患者对利福平耐药。在引入Xpert MTB/RIF的前后一年,疑似结核病患者数量从2138例增加了9%,达到2322例。两个时期的人口统计学特征、涂片阳性结果或抗酸杆菌等级均无变化。培养的标本数量从638例大幅下降至零,引入Xpert MTB/RIF之前有76例结核分枝杆菌培养呈阳性,之后则无。登记结核病病例的情况发生了显著变化,儿童患者增多(34%对21%),细菌学确诊病例减少(29%对43%)——P<0.001。自Xpert MTB/RIF在基里巴斯投入使用以来,检测次数较少,且这与对痰涂片显微镜检查无不良影响、停止分枝杆菌培养以及确诊结核病的类型和类别变化有关。